Immatics NVIMTX -2.76%60 Buyback Yield % is -11.25 as of Jul. 02, 2026. GuruFocus rates IMTX with a GF Score™ of 60/100 and a GF Value™ of $3.42 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 745 Biotechnology companies, Immatics NV ranks worse than 54.23% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Immatics NV's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMTX vs MNKD, JBIO, AVLN: Buyback Yield % Comparison
For the Biotechnology subindustry, Immatics NV's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immatics NV Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immatics NV's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Immatics NV's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immatics NV (IMTX) has a Buyback Yield % of -11.25 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Immatics NV and its competitors. According to the industry distribution chart, Immatics NV ranks #404 out of 745 companies in the Biotechnology industry, placing it in the top 54.2%.
Is Immatics NV's Buyback Yield % too high?
Immatics NV's current Buyback Yield % is -11.25. Based on the distribution chart, Immatics NV ranks #404 out of 745 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immatics NV has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immatics NV's Buyback Yield % compare to MNKD and JBIO?
According to the Biotechnology industry distribution chart, Immatics NV ranks #404 out of 745 companies for Buyback Yield %. This places Immatics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Immatics NV and its competitors. Immatics NV's current Buyback Yield % is -11.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immatics NV stock overvalued right now?
Based on GuruFocus' analysis, Immatics NV (IMTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.42, compared to a current price of $9.85 — trading 188% above its estimated fair value. The current Buyback Yield % is -11.25. Immatics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Immatics NV (IMTX), the current Buyback Yield % is -11.25 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immatics NV (IMTX) Overvalued in 2026?
Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued.
The current stock price of $9.85 is trading 188% above its estimated GF Value™ of $3.42.
GuruFocus considers Immatics NV to be Significantly Overvalued.
Key valuation signals for IMTX:
Buyback Yield %: -11.25
GF Value™: $3.42 vs. price of $9.85 (188% above fair value)
No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
60GF Score
Get the complete analysis for IMTX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMTX has been successfully added to your 
